Daltroban is a thromboxane receptor (TP) antagonist.1 It inhibits aggregation of isolated human platelets induced by the TP agonist U-46619 . Daltroban increases mean pulmonary arterial pressure (MPAP), mean arterial pressure (MAP), and hematocrit levels in anesthetized rats (ED50s = 20, 217, and 94 ?g/kg, respectively). It maintains post-reinfusion MAP and superior mesenteric artery flow in a cat model of hemorrhagic shock when administered at a dose of 1 mg/kg.2 Daltroban (0.25-2 mg/kg) increases survival and decreases circulating platelet count in a rabbit model of sodium arachidonate-induced sudden death.3
1.Bertolino, F., Valentin, J.P., Maffre, M., et al.Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivoBr. J. Pharmacol.115210-216(1995) 2.Bitterman, H., Yanagisawa, A., and Lefer, A.M.Beneficial actions of thromboxane receptor antagonism in hemorrhagic shockCirc. Shock20(1)1-11(1986) 3.Lefer, D.J., Mentley, R.K., and Lefer, A.M.Protective effects of a new specific thromboxane antagonist in arachidonate-induced sudden deathArch. Int. Pharmacodyn. Ther.287(1)89-95(1987)